Human monoglyceride lipase (MGL) is a recently identified lipase and very little is known about its regulation and function in cellular regulatory processes, particularly in context to human malignancy. In this study, we investigated the regulation and function of MGL in human cancer(s) and report that MGL expression was either absent or reduced in the majority of primary colorectal cancers. Immunohistochemical studies showed that reduction of MGL expression in the colorectal tumor tissues predominantly occurred in the cancerous epithelial cells. MGL was found to reside in the core surface of a cellular organelle named 'lipid body'. Furthermore, it was found to interact selectively with a number of phospholipids, including phosphatidic acid and phosphoinositol(3,4,5)P3, phosphoinositol(3,5)P2, phosphoinositol(3,4)P2 and several other phosphoinositides, and among all phosphoinositides analyzed, its interaction with PI(3,4,5)P3 was found to be the strongest. In addition, overexpression of MGL suppressed colony formation in tumor cell lines and knockdown of MGL resulted in increased Akt phosphorylation. Taken together, our results suggest that MGL plays a negative regulatory role in phosphatidylinositol-3 kinase/Akt signaling and tumor cell growth.
INTRODUCTION
Colorectal cancer is the most common gastrointestinal malignancy and the second most common cause of cancer-related deaths. 1, 2 Approximately 80 --90% of all colorectal cancers are sporadic. 3, 4 With equal incidence in men and women, almost 60% of the colon cancers originate in the descending (left) and rectosigmoid colon, and the most common tumor type is adenocarcinoma. 4 Recent molecular and genetic studies have revealed that the majority of the sporadic-type colorectal cancers follows the classical adenoma to carcinoma sequence. 3, 4 Although significant progress has been made in better understanding the molecular and genetic events underlying the malignant progression of colorectal cancer, the exact mechanism(s) that are responsible for the malignant transformation of colon mucosa need to be further elucidated.
Evidence suggests that dysregulated lipid metabolism appears to contribute to colorectal cancer development. 5 For example, secretory group II phospholipases A2 (PLA2) degrades phospholipid to generate lysophospholipids and its overexpression has been found in colorectal adenomas from familial adenomatous polyposis patients. 6 Elevated levels of lysophosphatidylcholine and phosphatidylcholine plasmalogen have been found in malignant colorectal tissues when compared with their matching normal tissues. 7 Somatic mutations in the p110 subunit of phosphatidylinositol-3 kinase have been found in a large portion of colon cancers; 8 and such mutations increase the kinase's activity to generate the phosphoinositol-3-phosphate products (such as PI (3, 4, 5) P3, PI(3,5)P2), which in turn activate its downstream target Akt that plays a very important role in the regulation of cell proliferation and cell survival. 9 Evidence suggests that phospholipids are important not only in the formation of the cytoplasmic membrane and membranes of various organelles, but also in the regulation of many cellular processes such as gene transcription, cell signaling, cell survival and proliferation. 5 However, the molecular mechanisms underlying the dysregulation of phospholipid metabolism remain largely unclear and need to be further investigated.
In this study, we have investigated the expression and function of monoglyceride lipase (MGL) in human cancer. Our results indicate that MGL mRNA and protein expression were significantly reduced or absent in multiple human malignancies, particularly in colon, lung and breast cancers. We also found that MGL overexpression suppressed colony formation in various tumor cell lines. Interestingly, MGL interacted with several PIs, particularly with PI (3, 4, 5) P3 with the highest affinity and knockdown of MGL resulted in increased Akt phosphorylation. Taken together, our studies suggest for the first time that MGL may play a negative regulatory role in tumor cell growth and cancer development.
RESULTS

Expression of MGL is absent or reduced in multiple human malignancies
We examined the expression of MGL in multiple normal human tissues. MGL mRNA was detected as an approximately 4.2 kb transcript using a commercially available multitissue mRNA membrane. As shown in Figure 1 , higher levels of MGL mRNA expression were seen in the heart, smooth muscle, brain, colon mucosa and spleen, and slightly less in the kidney, lung, liver and small intestine. Testis, prostate, thymus, ovary and peripheral blood showed low levels of MGL expression. To study whether MGL expression was altered in human tumors, we examined MGL expression in various cancer cell lines and primary cancer tissues. In contrast to the high-level expression of MGL seen in the normal colon mucosa (Figure 1a ), most of the colon cancer cell lines displayed either undetectable or very low levels of MGL mRNA (Figure 1b . We then examined MGL mRNA and protein expression in primary human matching normal and tumor samples. First, we used a commercially available colon tissue RNA membrane carrying samples from matching normal and tumor tissues from four patients and noted that MGL mRNA expression was absent or significantly reduced in colon tumor (T) (four out of four patients) compared with their respective matching normal (N) tissues ( Figure 1c ). We also sought to investigate MGL expression at the protein level and to that end analyzed matching normal and tumor samples from 61 patients and noted that 33 out of 61 primary colon tumor samples displayed reduced or absent levels of MGL when compared with their matching normal counterparts. Figure 1d shows representative results for individuals 1 --16 and western blot results for matched normal tumor tissues of all 61 patients are shown in Supplementary Figure 1 . We also investigated whether MGL expression was only dysregulated in colon cancer or other tumor types were also affected. We found that most of the human breast cancer cell lines examined displayed low levels of MGL mRNA expression ( Supplementary Figure 2A ). MGL protein expression was also reduced in primary breast cancers when compared with normal tissue samples (Supplementary Figure 2B ). Similar dysregulated expression was noted in lung cancer. Supplementary Figure 2C shows an easily detectable level of MGL expression in a normal lung cell line (NL20, lane 1), whereas it was not detectable in two out of four lung cancer cell lines (Supplementary Figure 2C , lanes 2 --5), and MGL expression was also reduced in primary lung cancer when compared with matching normal tissues in two out of three patients (Supplementary Figure 2D ).
To get a broader view of the MGL expression in human tumors, we used a commercially available Cancer Profiling Array membrane, which contains tumor and matching normal RNA-cDNA samples from 241 individuals representing 13 different tissue types. Figures 2A and B depict the representative results of Cancer Profiling Array showing that MGL expression was significantly reduced or absent in a large portion of colon and lung tumors (T) compared with their matching normal (N) tissues (left panels). Glyceraldehyde 3-phosphate dehydrogenase probing was also performed to show the loading of all samples (right panels). The overall results of the MGL expression profile in various malignancies are summarized in Table 1 . As is shown, when compared with their matching normal tissues, decreased or lost MGL mRNA and protein expression was found in 59.4% (60/101) of colon cancer, 79% (19/24) of lung cancer, 61% (32/52) of breast cancer, 50% (9/18) of rectal cancer and 50% (14/28) of gastric cancer. Interestingly, a decrease in MGL expression was found in a smaller proportion of kidney cancer tissues (35%, 7/20) and endometrium cancer tissues (23.8%, 10/42), and none (0/6) of the thyroid cancer samples was found to have altered MGL expression patterns. In the case of colon cancer, matching normal, tumor and metastatic samples were available from four patients and, as shown in Figure 2A , reduced MGL expression was found in both nonmetastatic (21/34) and metastatic (4/4) colon tumors when compared with their matching normal counterparts. Taken together, the presented results indicate that a loss of or reduction in MGL expression occurs commonly in various primary human malignancies, and in the case of colon cancer, also in metastatic tumors.
Next, we performed immunohistochemistry to investigate MGL expression in matched normal and primary tumor tissues. The specificity of MGL antibodies was demonstrated by western blot analysis that detected the endogenous and bacterial purified MGL protein, as well as by short hairpin RNA (shRNA) knockdown that further confirmed the specific signal for MGL protein ( Figure 2C , left, middle and right panels, respectively). Figure 2D shows representative results of MGL immunohistochemistry performed on frozen sections of matched normal and tumor tissues from two colon cancer patients. The top and lower left panels show transverse sections of normal colonic mucosa that contains regularly spaced glands of similar size and shape. As is shown, moderate to strong anti-MGL staining is noted in each colonic M   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15   16  17  18  19   20   21   22  23  24  25  26  27  28   29  30  31  32  33  34   M   M   M   M   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15   16  17  18  19   20   21   22  23  24  25  26  27  28   29  30  31  32  33 Patient #   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21   1  2  3  4  5  6  7  8  9  10  11  12  13  14 epithelial cell (red arrows). The fibroblasts in lamina propria were weakly positive in MGL staining. Figure 2D (top and lower right panels) shows sections of colonic adenocarcinoma that contains irregularly sized and shaped tumor glands distributed in desmoplastic stroma. The tumor glands show markedly decreased staining for MGL with focal positivity seen in tumor epithelial cells, capillaries and rarely fibroblasts. It is worth noting that the positive MGL staining in the connective tissue components of lamina propria was comparable between normal (left panels) and tumor (right panels) tissues, which serves as an internal control for MGL staining. These results thus indicate that: (1) MGL is strongly expressed in the normal colorectal epithelial cells and reduced in tumor epithelium, and (2) ( Figure 3Ad ). We tried to colocalize MGL with the mitochondria, the endoplasmic reticulum (ER) and lipid droplets (cytoplasmic lipid droplet) (also known as lipid bodies), 10 the cellular organelles that are known to exhibit punctate staining patterns. Recent studies have indicated that lipid bodies not only contain lipid content, but also various cellular protein involved in cell signaling. 10 Results presented in Figures 3B and C indicate that green fluorescent protein-tagged MGL did not predominantly colocalize with the RFP-tagged mitochondrial and ER markers ( Figure 3B ). By contrast, RFP-MGL was colocalized with lipid bodies labeled with fluorophore Bodipy (Figure 3Da --c), whereas the staining of RFP alone (Figure 3Dd --f) did not exhibit similar patterns. More detailed confocal microscopic analyses revealed that MGL predominantly distributed to the core surface of the cytoplasmic lipid droplet and formed 'MGL crescents' around the cytoplasmic lipid droplet ( Figure 3E ), which was more evident when lipid bodies were enlarged by treatment with oleic acid (Figure 3Eh --j). Thus, these novel findings indicate that MGL is a cytoplasmic lipid droplet-associated protein.
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Exogenously expressed MGL suppresses colony formation in colon and lung cancer cells
To determine the effect of MGL on tumor cell growth, we reintroduced exogenous MGL or the control empty vector into tumor cells exhibiting either undetectable or low levels of MGL, and the colony formation of transfected cells was then analyzed. Figure 4a shows the representative photographs of tissue culture plates depicting colony formation in the presence and absence of exogenous MGL. As is shown, transfection of exogenous MGL significantly reduced colony formation in HCT116 (colon) and H1299 (lung) cancer cell lines. Quantitative results from two independent experiments on HCT116 cells are summarized in Figure 4b , which indicate that overexpression of MGL suppressed colony formation in HCT116 colon cancer cells by 52 --61% when compared with the colonies formed by vector-alone expressing cells. These results suggest that MGL appears to exhibit growth suppression activity in tumor cells.
MGL interacts with phosphatidic acid and phosphoinositol lipids
We performed protein --lipid overlay assays to identify MGLassociated lipid(s). As shown in Figure 5a , eight different phosphoinositol lipids (PtdIns) and phosphatidic acid showed interaction with MGL on the PIP strips. By contrast, lysophosphatidic acid, lysophosphocholine, phosphatidylethanolamine, phosphatidylcholine and sphingosine 1-phosphate showed no binding to MGL on the same membrane (Figure 5a ). Phosphatidylserine, on other hand, showed weak binding with MGL ( Figure 5a ). We also further analyzed MGL --phosphoinositol binding affinity using the PIP Array membranes that had eight different immobilized phosphoinositides arrayed in amounts ranging from 100 to 1.6 pmol. Figure 5b shows that MGL displayed highest binding affinity with PtdIns(3,4,5)P 3 at 6.25 pmol, followed by PtdIns(3,5)P 2 and PtdIns(4,5)P 2 at 12.5 pmol. MGL showed lower binding affinity with PtdIns(5)P and PtdIns (4) Purified MGL protein was incubated with PI Array membrane, which was spotted with decreased amounts of various phosphoinositide derivatives. MGL --lipid interaction was detected as described in (a). Protein --lipid overlay assays were performed on the duplicated membranes and similar results were observed.
with PtdIns (no phosphate) on the same membrane. These results were reproducible and suggest that MGL interacts with phospholipids, particularly with certain species of phosphoinositides, such as PtdIns(3,4,5)P 3 and PtdIns(3,5)P 2 . Position-3-phosphorylated phosphoinositides are known to be important for activation of Akt, a kinase critical for the regulation of cell growth and cell survival.
Effect of MGL knockdown on Akt phosphorylation
Next, we sought to determine the effect of MGL on phosphatidylinositol-3 kinase/Akt using the lentivirus-mediated MGL knockdown approach and HT29 colon cancer cells and MDA-MB-231 breast cancer cells were used in these experiments. These lines were chosen because they exhibit easily detectable levels of MGL protein and represent colon and breast cancers in which MGL expression is altered. Cells were infected either with viruses carrying scramble shRNA or two different MGL-specific shRNAs that targeted different regions of MGL mRNA. Akt phosphorylation was then determined in the MGL KD cell or the scramble RNA interference control cells. Figure 6 shows that depletion of MGL significantly enhanced the phosphorylation of Akt, but did not affect the protein levels of total Akt protein upon insulin stimulation. The effect of MGL KD on enhancement of Akt phosphorylation was observed in both HT29 colon cancer cells (Figure 6a ) and MDA-MB-231 breast cancer cells (Figure 6b ). Thus, these results indicate that phosphorylation of Akt may be constitutively suppressed by MGL and MGL KD appears to alleviate this suppression, leading to activation of Akt.
DISCUSSION
In this study, we have investigated MGL expression and function in human cancer. Our results indicate that MGL expression is either absent or reduced in the majority (59.4%, 60/101) of primary colorectal cancer examined. In addition, we also note that reduction in MGL expression also occurred in other types of cancer, including tumors of the lung 79% (19/24), breast 61% (32/ 52), stomach (50%, 14/28) and ovary (50% (7/14). Our results also indicate that MGL reduction occurred at both mRNA and protein levels. Decrease in MGL protein expression is likely to be a consequence of reduced mRNA levels in these tumor cells, although we cannot rule out the possibility that MGL alteration may also occur at the protein level. In addition, we also note that MGL expression was increased in a smaller portion (14% (14/101) from the combined results of all our studies) of primary colorectal tumors. Currently, we do not know why a small subset of the colorectal tumors has very different MGL expression pattern. Future studies are needed to determine the mutational status and regulation of MGL in human cancers. Nevertheless, our results presented here have demonstrated that loss or decreased MGL expression is a common feature of multiple human malignancies. A recent study by Nomura et al. 11 investigated MGL's role in cancer cells. Their results suggested that elevated MGL lipase activity was associated with more aggressive behavior and metastatic potential of the cancer cells. However, the expression status of endogenous MGL in tumor cells and in primary human tumor tissues was not investigated in their study. 11 Interestingly, we found that in four out of four colon cancer patients, MGL expression was reduced in primary as well as metastatic lesions when compared with matching normal tissues (Figure 2A) . These findings therefore indicate that in these patients, metastasis occurred in the absence of elevated levels of MGL. Further studies are needed to analyze MGL expression in larger cohort of metastatic samples to firmly establish the status of MGL in metastases.
To date, very little is known about MGL in the context of its role in cellular regulatory processes. MGL has been implicated in degrading cannabinoid 2-arachidonoyglycerol, which generates free fatty acids. 11 However, whether the functional role of MGL is limited to its lipase activity for 2AG is a debatable issue. Our results show that MGL binds to a number of phospholipids, including phosphatidic acid and phosphoinositide derivatives such as PI (3, 4, 5) P3, PI(3,5)P2, PI (3, 4) P2 and other phosphoinositides. The 3-phosphorylated phosphoinositides, products of phosphatidylinositol-3 kinase, are important signaling molecules that activate Akt kinase, a serine/threonine kinase that is stimulated by the binding of the 3-phosphorylated phosphoinositides. 9 Akt phosphorylation/activation plays an important role in the regulation of cell proliferation and cell survival. 9 In this study, we show that depletion of MGL, via lentivirus-mediated knockdown, increased Akt phosphorylation ( Figure 6 ). Our results thus suggest that MGL plays a negative role in the regulation of Akt phosphorylation. In addition, MGL may also exhibit functions other than its lipase activity and lipid association. Previous studies have shown that cytoplasmic PLA2 (cPLA2) can exhibit its function by interacting with proteins. For example, it has been shown that cPLA2 interacts with cPLA2-interacting protein, the b-unit of BK channel and integrin aIIbb3. 12 --14 Interactions between cPLA2 and cPLA2-interacting protein have been shown to enhance mesangial cells' sensitivity to serum withdrawal-induced apoptosis 12 and cPLA2 and integrin aIIbb3 interaction enhanced each other's functions during integrin aIIbb3 signaling. 13 The issue of whether MGL could exhibit its growth regulatory function via protein --protein interaction remains to be carefully investigated.
In summary, several lines of evidence presented in our studies do not support an oncogenic role of MGL in human cancers: (1) reduced/lost MGL expression widely occurred in a large portion of human cancers; (2) exogenously expressed MGL in tumor cells lacking MGL suppressed their growth; and (3) MGL knockdown activated Akt phosphorylation. Whether MGL has dual roles in cell growth regulation in different cell types is an issue that warrants further investigation. Our data, nevertheless, support the notion that MGL has growthsuppressive role and its loss or reduction may favor tumor formation and/or progression in cells lacking this protein. Clearly, further studies are needed to investigate the roles of MGL in human malignancy.
MATERIALS AND METHODS
Antibodies and reagents
The green fluorescent protein and b-actin antibodies were from Boehringer Mannheim (Indianapolis, IN, USA) and Sigma (St Louis, MO, USA), respectively; the hemagglutinin-tag antibody (HA.11) was from Covance (Berkeley, CA, USA). The fluorescein isothiocyanate-conjugated goat anti-rabbit secondary antibody was from Pierce (Rockford, IL, USA), and the peroxidase-conjugated goat anti-rabbit antibody was from Vector Laboratories (Burlingame, CA, USA). The MGL antibody was generated by immunizing rabbits with bacterial purified full-length MGL protein through a commercial source (Pocono Rabbit Farm and Laboratory, Canandensis, PA, USA). The VECTASTAIN ABC kit was from Vector Laboratories (Burlingame, CA, USA). The Bodipy lipid probe was from Molecular Probes Inc. (Eugene, OR, USA). The matching human patient normal and tumor samples were from The Cooperative Human Tissue Network, an organization sponsored by the National Cancer Institute.
Cell culture conditions
Human cancer cell lines HT29 (colon), JCA-1 (bladder), H1299 (lung) and MDA-MB-231 (breast) were regularly maintained in Dulbecco's modified Eagle's medium (Cellgro, Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum (Gemeni Bioproducts Inc., Calabasas, CA, USA). HCT116 cells (colon) were maintained in McCoy's medium (Cellgro) supplemented with 10% fetal bovine serum (Gemeni Bioproducts Inc.).
Expression plasmids
RFP-tagged MGL was generated by inserting the full-length MGL cDNA into the pDsRedN1 vector (Clontech, Mountain View, CA, USA). MGL expression vectors used for colony formation assays were generated by inserting the MGL open-reading frame into the multiple cloning site of pCEP4 (with hygromycin selection marker) or pcDNA3.1 (with neomycin selection marker) (Invitrogen Corporation, Carlsbad, CA, USA).
Lentivirus-mediated shRNA silencing MGL expression was silenced by the lentivirus-mediated shRNA approach. The scramble shRNA construct was purchased from Addgene Inc.
(Cambridge, MA, USA). All other shRNA constructs were purchased from Open Biosystems Inc. (Huntsville, AL, USA). The two different nucleotide sequences to target the human MGL used in this study were as follows: 5 0 -CCAATCCTGAATCTGCAACAA-3 0 and 5 0 -CAACTCCGTCTTCCATGAAAT-3 0 . Virus production and infection were performed as per the Addgene's protocol.
MGL mRNA expression analyses
The human multi-tissue Northern blot membrane (2 mg poly-A mRNA per lane) was purchased from Panomics (Fremont, CA, USA). The Human Cancer Profiling Array membrane (contains 241 cancer patients matching normal and tumor tissues) was purchased from BD Bioscience/Clontech. The Northern blot membrane containing matching normal and tumor RNAs extracted from four colon cancer patients was purchased from Invitrogen Corporation. Northern blot analyses were performed according to standard procedures as described previously. 15 To detect MGL mRNA expression, full-length MGL cDNA fragment was used as a probe. Full-length glyceraldehyde 3-phosphate dehydrogenase probe was also used for loading control.
Western blot, immunofluorescent staining and immunohistochemistry
Western blot analyses were performed as described previously. 16 For immunofluorescent staining of endogenous MGL protein, cells were blocked with 10% goat serum in phosphate-buffered saline, and then incubated with MGL antibodies (1:500 diluted in phosphate-buffered saline with 1.5% goat serum), followed by fluorescein isothiocyanatelabeled anti-rabbit antibodies (1:500 diluted in phosphate-buffered saline with 1.5% goat serum). Cells were counterstained with 4 0 ,6diamidino-2-phenylindole nuclear dye and analyzed under an Olympus fluorescent microscope or a fluorescent confocal scanning microscope (Zeiss LSM510).
For immunohistochemistry staining, 6 mm frozen tissue sections were fixed in 4% paraformaldehyde, followed by 1% hydrogen peroxide for 10 min. All sections were blocked with 10% goat serum in phosphatebuffered saline for 20 min before incubation with MGL antibodies, followed by peroxidase-labeled anti-rabbit antibodies. The sections were then incubated with Vectastain elite ABC reagent for 30 min and then the peroxidase substrate DAB (3,3 0 -diaminobenzidine) solution was added until the desired stain intensity developed. Finally, all slides were counterstained with hematoxylin (Sigma).
Colony formation assay
Colony formation assays were performed as described previously. 16 Cells were transfected with same amounts of control vector or MGL expression vector carrying the antibiotic selection markers via Lipofectamine 2000 as per the protocol of the manufacturer (Invitrogen). Cells were subsequently selected with antibiotics (hygromycin 200 mg/ml or G418 500 mg/ml) for 14 --20 days and then stained with crystal violet.
Protein --lipid overlay assays
Protein --lipid overlay assays were conducted using commercial phospholipid-containing PIP Strips or PI-containing PIP Array membrane (Echolon Biosciences, Salt Lake City, UT, USA). All membranes were blocked with 3% fatty acid-free bovine serum albumin in Tris-buffered saline and Tween-20 buffer (150 mM NaCl, 10 mM Tris-HCl, pH 8.0, and 0.1% Tween-20) for 1 h at room temperature. Blocked membranes were incubated overnight at 4 1C with 0.5 mg/ml purified MGL protein. The membranes were then washed 3 Â (10 min each time) with blocking buffer, followed by incubation with MGL antibodies (1:2000 diluted in Tris-buffered saline and Tween-20 with 4% fatty acid-free bovine serum albumin) overnight at 4 1C on a shaker. Following three washes over 30 min with blocking buffer, the membranes were incubated for 1 h with peroxidase-conjugated goat anti-rabbit antibodies (1:2000 diluted in blocking buffer) and visualized with Supersignal West Pico chemiluminescent substrate (Pierce, Rockford, IL, USA) according to the manufacturer's instructions.
